Clinical utility of raltegravir for the treatment of HIV infection in children and adolescents

References

• Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359(21):2233–2244.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Therapy and Medical Management of HIV- Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Washington: United States Department of Health and Human Services; 2013. Available at: http://aidsinfo. nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf. Accessed May 12, 2013.
   Google Scholar
• Brady MT, Oleske JM, Williams PL, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir ImmuneDefic Syndr. 2010;53(1):86–94.
   PubMed Web of Science ®Google Scholar
• Viani RM, Araneta MR, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004;39(5):725–731.
   PubMed Web of Science ®Google Scholar
• Nachman SA, Lindsey JC, Moye J, et al; Pediatric AIDS Clinical Trials Group 377 Study Team. Growth of human immunodeficiency virus- infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J. 2005;24(4):352–357.
   PubMed Web of Science ®Google Scholar
• Lindsey JC, Malee KM, Brouwers P, Hughes MD; PACTG 219C Study Team. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics. 2007;119(3):e681–e693.
   Web of Science ®Google Scholar
• Delaugerre C, Chaix ML, Blanche S, et al; ANRS French Perinatal Cohort. Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. Retrovirology. 2009;6:85.
   PubMed Web of Science ®Google Scholar
• Persaud D, Palumbo P Ziemniak C, et al; Pediatric AIDS Clinical Trials Group P1030 Team. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis. 2007;195(10):1402–1410.
   Web of Science ®Google Scholar
• Van Dyke RB, Wang L, Williams PL; Pediatric AIDS Clinical Trials Group 219C Team. Toxicities associated with dual nucleoside reverse transcriptase inhibitor regimens in HIV-infected children. J Infect Dis. 2008;198(11):1599–1608.
   Web of Science ®Google Scholar
• Foster C, Lyall H. HIV and mitochondrial toxicity in children. J Anti- microb Chemother. 2008;61(1):8–12.
   Web of Science ®Google Scholar
• Isentress® (raltegravir) [product information]. Whitehouse Station, NJ: Merck and Co, Inc; 2011.
   Google Scholar
• Cherepanov P, Maertens GN, Hare S. Structural insights into the retroviral DNA integration apparatus. Curr Opin Struct Biol. 2011;21(2):249–256.
   PubMed Web of Science ®Google Scholar
• Krishnan L, Engelman A. Retroviral integrase proteins and HIV-1 DNA integration. J Biol Chem. 2012;287(49):40858–40866.
   PubMed Web of Science ®Google Scholar
• Craigie R, Bushman FD. HIV DNA Integration. Cold Spring Harb Perspect Med. 2012;2(7):a006890.
   Web of Science ®Google Scholar
• Malet I, Calvez V, Marcelin AG. The future of integrase inhibitors of HIV-1. Curr Opin Virol. 2012;2(5):580–587.
   PubMed Web of Science ®Google Scholar
• Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287(5453):646–650.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther. 2008;83(2):293–299.
   PubMed Web of Science ®Google Scholar
• Isentress (raltegravir) [prescribing information]. Whitehouse Station, NJ: Merck and Co, Inc; 2012.
   Google Scholar
• Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43(5):509–515.
   PubMed Web of Science ®Google Scholar
• Ter Heine R, Mulder JW, van Gorp EC, Wagenaar JF, Beijnen JH, Huitema AD. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. Br J Clin Pharmacol. 2010;69(5):475–483.
   Web of Science ®Google Scholar
• Adams JL, Greener BN, Kashuba AD. Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS. 2012;7(5):390–400.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Rockstroh JK, Reynes J, et al; QDMRK Investigators. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis. 2011;11(12):907–915.
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, Nguyen B, Markowitz M, et al. Sustained efficacy and tolerability of raltegravir after 240 weeks of combination ART in treatment-naive HIV-1 infected patients; final analysis of protocol 4. Presented at: The 6th International AIDS Society; Rome, Italy; July 17–20, 2011. Abstract WEPDB0102.
   Google Scholar
• Rockstroh JK, Lennox JL, Dejesus E, et al; STARTMRK Investigators. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53(8):807–816.
   PubMed Web of Science ®Google Scholar
• Rizk ML, Hang Y, Luo WL, et al. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatmentnaive HIV-infected patients. Antimicrob Agents Chemother. 2012;56(6):3101–3106.
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Gisslen M, Spudich S, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS ONE. 2009;4(9):e6877.
   PubMed Web of Science ®Google Scholar
• Croteau D, Letendre S, Best BM, et al; CHARTER Group. Total ralte- gravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. AntimicrobAgents Chemother. 2010;54(12):5156–5160.
   PubMed Web of Science ®Google Scholar
• Mora-Peris B, Mackie NE, Suan D, Cooper DA, Brew BJ, Winston A. Raltegravir resistance in the cerebrospinal fluid. Infection. 2013;41(3):731–734.
   Web of Science ®Google Scholar
• Siccardi M, D’ Avolio A, Rodriguez-Novoa S, et al. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. Ther Drug Monit. 2012;34(2):232–235.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Gervasoni C, Meraviglia P, et al. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother. 2012;67(2):460–464.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Baldelli S, Cerea M, et al. Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing. Antimicrob Agents Chemother. 2012;56(12):6132–6136.
   PubMed Web of Science ®Google Scholar
• Brainard DM, Friedman EJ, Jin B, et al. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J Clin Pharmacol. 2011;51(3):422–427.
   PubMed Web of Science ®Google Scholar
• Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007;35(9):1657–1663.
   PubMed Web of Science ®Google Scholar
• Wenning LA, Petry AS, Kost JT, et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther. 2009;85(6):623–627.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Hanley WD, Petry AS, et al. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob Agents Chemother. 2009;53(5):1747–1752.
   Web of Science ®Google Scholar
• Barau C, Braun J, Vincent C, et al; ANRS 148 Study Group. Pharmacokinetic Study of Raltegravir in HIV+ Patients with End Stage Liver Disease: LIVERAL ANRS 148 Study. Presented at: 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, GA; March 3–6, 2013. Paper #528.
   Google Scholar
• Acosta A, Wiznia A, Nachman S, et al. Raltegravir (RAL) pharmacokinetics (PK) in adolescents: preliminary results from IMPAACT protocol 1066. Presented at: 9th International Workshop on Clinical Pharmacology of HIV Therapy; New Orleans, LA; April 7–9, 2008.
   Google Scholar
• Nachman S, Acosta E, Wiznia A, et al. Raltegravir phamacokinetics (PK) and safety in adolescents: Preliminary results from IMPAACT P1066. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); October 25–28, 2008; Washington, DC.
   Google Scholar
• Nachman S, Samson P, Acosta E, et al. P1066 Group. Pharmacokinetic (PK), Safety, and Efficacy Data on Cohort IIA; Youth Aged 6 to 11 Years from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; February 16–19, 2010. Paper #873.
   Google Scholar
• Nachman S, Acosta E, Samson P, et al. P1066 Group. Interim Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (OCT) Formulation in Children 6 to 11 Years. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; February 16–19, 2010. Paper #161LB.
   Google Scholar
• Nachman S, Acosta E, Zheng N, et al; P1066 Study Team. Interim Results from IMPAACT P1066: RAL Oral Chewable Tablet Formulation for 2- to 5-Year-olds. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA; February 27-March 2, 2011. Paper#715.
   Google Scholar
• Spector S, Acosta E, Zheng N, et al; IMPAACT P1066 Study Team. Raltegravir Oral Granules Formulation in Children 6 months to <2 Years of Age: Interim Results from IMPAACT P1066. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; Seattle, WA; March 5–8, 2012. Paper #987.
   Google Scholar
• Wiznia A, Samson P, Acosta E, et al. Safety and efficacy of raltegravir in pediatric HIV infection. Preliminary analysis from the international maternal pediatric adolescent AIDS clinical trials group, P1066. Abstract presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Quebec; February 8–11, 2009. Abstract 874.
   Google Scholar
• Briz V Leon-Leal JA, Palladino C, et al. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents. Pediatr Infect Dis J. 2012;31(3):273–277.
   PubMed Web of Science ®Google Scholar
• Nachman S, Acosta E, Zheng N, et al. IMPAACT P1066: raltegravir (RAL) safety and efficacy in HIV infected (+) youth two to 18 years of age through week 48. Presented at: XIX International AIDS Conference; July 22–27, 2012; Washington, DC. Abstract TUAB0205.
   Google Scholar
• Brainard DM, Gendrano III N, Jin B, et al. A Pharmacokinetic Comparison of Adult and Pediatric Formulations of RAL in Healthy Adults. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; February 16–19, 2010. Paper #872.
   Google Scholar
• McKeown DA, Rosenvinge M, Donaghy S, et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS. 2010;24(15):2416–2418.
   Web of Science ®Google Scholar
• Hegazi A, Mc Keown D, Doerholt K, Donaghy S, Sadiq ST, Hay P. Raltegravir in the prevention of mother-to-child transmission of HIV-1: effective transplacental transfer and delayed plasma clearance observed in preterm neonates. AIDS. 2012;26(18):2421–2423.
   Web of Science ®Google Scholar
• Clarke D, Acosta E, Rizk M, et al; IMPAACT P1097 Study Team. Ralte- gravir Pharmacokinetics and Safety in Neonates (IMPAACT P1097). Presented at: 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, GA; March 3–6, 2013. Paper #974.
   Google Scholar
• Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53(7):2852–2856.
   PubMed Web of Science ®Google Scholar
• Grinsztejn B, De Castro N, Arnold V et al. Efficacy and Safety of Raltegravir vs Efavirenz for the Treatment of HIV/TB Patients: 48-Week Results of the ANRS 12 180 Reflate TB Trial. Presented at: 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, GA; March 2-6, 2013. Paper #853.
   Google Scholar
• Gervasoni C, Riva A, Impagnatiello C, Galli M, Cattaneo D. Is Chewed Raltegravir an Option to Care for HIV-Infected Patients With Active Tuberculosis? Clin Infect Dis. 2013. Epub May 10, 2013. Brainard DM, Kassahun K, Wenning LA, et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation. J Clin Pharmacol. 2011;51(6):943–950.
   Web of Science ®Google Scholar
• Weiner M, Peloquin C, Engle M, Egelund E, Thomas P, Mac Kenzie W. The pharmacokinetic interaction between raltegravir and rifapentine in healthy volunteers. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; Seattle, WA; March 5–8, 2012. Paper 615.
   Google Scholar
• Nguyen BY, Isaacs RD, Teppler H, et al. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann NY AcadSci. 2011;1222:83–89.
   PubMed Web of Science ®Google Scholar
• Jackson A, Moyle G, Dickinson L, et al. Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ ritonavir or raltegravir in HIV-infected subjects. Antivir Ther (Lond). 2012;17(1):19–24.
   Web of Science ®Google Scholar
• Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J Clin Pharmacol. 2011;51(10):1376–1402.
   Web of Science ®Google Scholar
• Wenning LA, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother. 2008;52(9):3253–3258.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Petry AS, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2008;52(12):4338–4343.
   PubMed Web of Science ®Google Scholar
• Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother. 2008;52(12):4228–4232.
   Web of Science ®Google Scholar
• Do VT, Higginson RT, Fulco PP. Raltegravir dosage adjustment in HIV-infected patients receiving etravirine. Am J Health Syst Pharm. 2011;68(21):2049–2054.
   Web of Science ®Google Scholar
• Rhame F, Long M, Acosta E. RAL-KAL: pharmacokinetics (PK) of coadministered raltegravir (RAL) and lopinavir-ritonavir (KAL) in healthy adults. Presented at: AIDS 2008 – XVII International AIDS Conference; Mexico City, Mexico; August 3–8, 2008. Abstract TUPE0075.
   Google Scholar
• Ren Y, Nuttall JJ, Egbers C, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir ImmuneDefic Syndr. 2008;47(5):566–569.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Mistry GC, et al. uridine diphosphate glucuronosyltransferase isoenzyme 1A modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis. 2008;47(1):137–140.
   Google Scholar
• Zhu L, Butterton J, Persson A, et al. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals. Antivir Ther (Lond). 2010;15(8):1107–1114.
   Web of Science ®Google Scholar
• Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Conti F, Clementi E. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit. 2010;32(6):782–786.
   Web of Science ®Google Scholar
• Neely M, Decosterd L, Fayet A, et al. Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. Antimicrob Agents Chemother. 2010;54(11):4619–4625.
   PubMed Web of Science ®Google Scholar
• Fayet Mello A, Buclin T, Franc C, et al. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. J Antimicrob Chemother. 2011;66(7):1573–1581.
   Web of Science ®Google Scholar
• Jackson A, Watson V, Back D, et al. Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals. J Acquir Immune Defic Syndr. 2011;58(5):450–457.
   PubMed Web of Science ®Google Scholar
• Johannessen SI, Landmark CJ. Antiepileptic drug interactions – principles and clinical implications. CurrNeuropharmacol. 2010;8(3):254–267.
   Web of Science ®Google Scholar
• DiCenzo R, Peterson D, Cruttenden K, et al. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004;48(11):4328–4331.
   PubMed Web of Science ®Google Scholar
• van Luin M, Colbers A, Verwey-van Wissen CP, et al. The effect of raltegravir on the glucuronidation of lamotrigine. J Clin Pharmacol. 2009;49(10):1220–1227.
   Web of Science ®Google Scholar
• Iwamoto M, Kassahun K, Troyer MD, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol. 2008;48(2):209–214.
   Web of Science ®Google Scholar
• Birbeck GL, French JA, Perucca E, et al; Quality Standards Subcommittee Of The American Academy Of Neurology; Ad Hoc Task Force Of The Commission On Therapeutic Strategies Of The International League Against Epilepsy. Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia. 2012;53(1):207–214.
   Google Scholar
• Young B, Vanig T, DeJesus E, et al. 96-Week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naive HIV-1 infected patients: the SHIELD trial. HIV Clin Trials. 2011;12(4):228–233.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E, et al; Protocol 004 Part II Study Team. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46(2):125–133.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-l-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2011. Available from: http://www.aidsinfo.nih.gov/ContentFiles/Adultand- AdolescentGL.pdf. Accessed May 10, 2013.
   Google Scholar
• Thompson MA, Aberg JA, Cahn P, et al; International AIDS SocietyUSA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304(3):321–333.
   PubMed Web of Science ®Google Scholar
• Rokas KE, Bookstaver PB, Shamroe CL, et al. Role of raltegravir in HIV-1 management. Ann Pharmacother. 2012;46(4):578–589.
   Web of Science ®Google Scholar
• Taiwo B, Zheng L, Gallien S, et al; ACTG A5262 Team. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011;25(17):2113–2122.
   PubMed Web of Science ®Google Scholar
• Bedimo R, Drechsler H, Turner D, et al. RADAR study: raltegravir combined with boosted darunavir has similar safety and antiviral efficacy as tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Presented at: The 6 th International AIDS Society; Rome, Italy; July 17–20, 2011. Abstract MOPE214.
   Google Scholar
• Reynes J, Lawal A, Pulido F, et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the progress study, 48-week results. HIV Clin Trials. 2011;12(5):255–267.
   PubMed Web of Science ®Google Scholar
• Gathe J, Reynes J, Pulido F, et al. Lopinavir/ritonavir (LPV/r) combined with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC) in antiretroviral-naive subjects: 96-week efficacy and safety results of the PROGRESS study. Presented at: The Infectious Disease Society of America; Boston, MA; October 20–23, 2011. Abstract 406.
   Google Scholar
• Bowman V Rieg G, Jain S, et al. 48 week results of a pilot randomized study of a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen of raltegravir (RAL) + lopinavir/ritonavir (LPV/r) versus efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) in antiretro. Presented at: The 6th International AIDS Society; Rome, Italy; July 17–20, 2011. Abstract CDB336.
   Google Scholar
• Kozal MJ, Lupo S, DeJesus E, et al. The SPARTAN study: a pilot study to assess the safety and efficacy of an investigational NRTI- and RTVs- paring regimen of atazanavir (ATV) experimental dose of 300 mg BID plus raltegravir (RAL) 400 mg BID (ATV + RAL) in treatment-naive HIV-infected subjects. Presented at: The International AIDS Conference; Vienna, Austria; July 18–23, 2010. Abstract THLBB204.
   Google Scholar
• Gutiérrez C, Hernández-Novoa B, Pérez-Elías MJ, et al. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naive and -experienced patients infected with B and non-B HIV-1 variants. HIV Clin Trials. 2013;14(1):10–16.
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, et al; BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339–354.
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Teppler H, et al; BENCHMRK Study Teamsa. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010;50(4):605–612.
   PubMed Web of Science ®Google Scholar
• Gallien S, Braun J, Delaugerre C, et al; EASIER ANRS 138 Study Group. Efficacy and safety of raltegravir in treatment-experienced HIV- 1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother. 2011;66(9):2099–2106.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Young B, Cooper DA, et al; SWITCHMRK 1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir- ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375(9712):396–407.
   PubMed Web of Science ®Google Scholar
• Martínez E, Larrousse M, Llibre JM, et al; SPIRAL Study Group. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV- infected patients: the SPIRAL study, AIDS. 2010;24(11):1697–1707.
   PubMed Web of Science ®Google Scholar
• Nguyen A, Calmy A, Delhumeau C, et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS. 2011;25(12):1481–1487.
   PubMed Web of Science ®Google Scholar
• Towner W, Klein D, Kerrigan HL, Follansbee S, Yu K, Horberg M. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J Acquir Immune Defic Syndr. 2009;51(4):367–373.
   Web of Science ®Google Scholar
• Métifiot M, Marchand C, Maddali K, Pommier Y. Resistance to integrase inhibitors. Viruses. 2010;2(7):1347–1366.
   Web of Science ®Google Scholar
• Fransen S, Gupta S, Danovich R, et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol. 2009;83(22):11440–11446.
   PubMed Web of Science ®Google Scholar
• Baldanti F, Paolucci S, Gulminetti R, Brandolini M, Barbarini G, Maserati R. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. J Med Virol. 2010;82(1):116–122.
   Web of Science ®Google Scholar
• Wirden M, Simon A, Schneider L, et al. Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. J Antimicrob Chemother. 2009;64(5):1087–1090.
   Web of Science ®Google Scholar
• Thuret I, Tamalet C, Chaix M, et al. Raltegravir in children and adolescents: the French expanded access program. In: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Quebec; February 8–11, 2009. Abstract 873.
   Google Scholar
• Lennox JL, DeJesus E, Lazzarin A, et al; STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796–806.
   PubMed Web of Science ®Google Scholar
• Pérez-Matute P, Pérez-Martínez L, Blanco JR, Oteo JA. Neutral actions of Raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes. Curr HIV Res. 2011;9(3):174–179.
   PubMed Web of Science ®Google Scholar
• Minami R, Yamamoto M, Takahama S, Ando H, Miyamura T, Suematsu E. Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir. J Infect Chemother. 2011;17(2):183–188.
   PubMed Web of Science ®Google Scholar
• Curran A, Martinez E, Saumoy M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS. 2012;26(4):475–481.
   PubMed Web of Science ®Google Scholar